Abstract

Toward personalization of asthma treatment according to trigger factors

Niespodziana K Borochova K Pazderova P Schlederer T Astafyeva N Baranovskaya T Barbouche MR Beltyukov E Berger A Borzova E Bousquet J Bumbacea RS Bychkovskaya S Caraballo L Chung KF Custovic A Docena G Eiwegger T Evsegneeva I Emelyanov A Errhalt P Fassakhov R Fayzullina R Fedenko E Fomina D Gao Z Giavina-Bianchi P Gotua M Greber-Platzer S Hedlin G Ilina N Ispayeva Z Idzko M Johnston SL Kalayci O Karaulov A Karsonova A Khaitov M Kovzel E Kowalski ML Kudlay D Levin M Makarova S Matricardi PM Nadeau KC Namazova-Baranova L Naumova O Nazarenko O O'Byrne PM Osier F Pampura AN Panaitescu C Papadopoulos NG Park HS Pawankar R Pohl W Renz H Riabova K Sampath V Sekerel BE Sibanda E Siroux V Sizyakina LP Sun JL Szepfalusi Z Umanets T Van Bever HPS van Hage M Vasileva M von Mutius E Wang JY Wong GWK Zaikov S Zidarn M Valenta R
J Allergy Clin Immunol. 2020;1451529-1534

Permenent descriptor

Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma.